N'-(1-methyl-1H-imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)butane-1,4-diamine | 558446-90-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N'-(1-methyl-1H-imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)butane-1,4-diamine
• 英文别名: N1-(1-methyl-1H-imidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)butane-1,4-diamine；N-(1-methyl-1H-imidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)butane-1,4-diamine；N1-(1-methyl-1H-imidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydro-quinolin-8-yl)butane-1,4-diamine；N1-(1-Methyl-1H-imidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)butan-1,4-diamin；N'-[(1-methylimidazol-2-yl)methyl]-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine
• CAS: 558446-90-5
• 化学式: C₁₈H₂₇N₅
• 分子量: 313.446
• InChiKey: WFYJYSAVZPHLNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  60
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 N'-(1-methyl-1H-imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)butane-1,4-diamine
  参考文献：
  名称：

  Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity

  摘要：

  Using AMD070 as a starting point for structural modification, a novel series of isoquinoline CXCR4 antagonists was developed. A structure-activity scan of alternate lower heterocycles led to the 3-isoquinolinyl moiety as an attractive replacement for benzimidazole. Side chain optimization in the isoquinoline series led to a number of compounds with low nanomolar anti-HIV activities and promising rat PK properties. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.118

文献信息

• CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY
  申请人：BRIDGER Gary

  公开号：US20080167341A1

  公开（公告）日：2008-07-10

  The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  该发明涉及由一个核心氮原子和三个侧链基团组成的杂环化合物，其中三个侧链基团中有两个是苯并咪唑甲基和四氢喹啉基，第三个侧链基团含有N，并且可以含有额外的环。这些化合物结合趋化因子受体，包括CXCR4和CCR5，并且表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护效果。
• Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy
  申请人：Genzyme Corporation

  公开号：US20150038509A1

  公开（公告）日：2015-02-05

  The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  该发明涉及杂环化合物，其由一个核心氮原子和三个下垂基团组成，其中三个下垂基团中的两个优选为苯并咪唑甲基和四氢喹啉基，第三个下垂基团含有N，并且可以包含其他环。这些化合物结合趋化因子受体，包括CXCR4和CCR5，并且对人类免疫缺陷病毒（HIV）感染目标细胞具有保护作用。
• Chemokine receptor binding heterocyclic compounds with enhanced efficacy
  申请人：Genzyme Corporation

  公开号：US10322111B2

  公开（公告）日：2019-06-18

  The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  本发明涉及由一个核心氮原子和三个悬垂基团组成的杂环化合物，其中三个悬垂基团中的两个最好是苯并咪唑甲基和四氢喹啉基，第三个悬垂基团含有N，并可选择含有附加环。 这些化合物与趋化因子受体（包括 CXCR4 和 CCR5）结合，对靶细胞感染人类免疫缺陷病毒（HIV）具有保护作用。
• US7354932B2
  申请人：——

  公开号：US7354932B2

  公开（公告）日：2008-04-08
• US7354934B2
  申请人：——

  公开号：US7354934B2

  公开（公告）日：2008-04-08